One CAR T-cell product targeting PSMA, P-PSMA-101, is from Poseida Therapeutics (San Diego, CA, USA), which was designed to target prostate cancer cells expressing the cell-surface antigen PSMA (https://poseida.com/science/pipeline (1 December 2022)). Here, FOLH1 is linked to Familial prostate cancer.